Global Hormonal Contraceptive Market, By Product (Combined Oral Contraceptives, Oral, Contraceptives, Implanted Contraceptives, Injected Contraceptives, Intrauterine, Transdermal Patch Vaginal Ring), Hormone (Androgens, Estrogens, Progestogens, Antiandrogens, Gonadotropins, Others), Age Group (15-24 Years, 25-34 Years, 35-44 Years, Above 44 Years), Gender (Male and Female), End-User (Hospitals, Homecare, Clinics, Gynecology Centers, Ambulatory Surgical Centers (ASC)) – Industry Trends and Forecast to 2030.
Hormonal Contraceptive Market Analysis and Size
According to the World Health Organization, among 1.9 billion reproductive-age women of 15 - 49 years worldwide in 2019, around 1.1 billion women require family planning. The major companies are collaborating with huge organizations to make people aware of the contraceptives that help avoid pregnancy. Furthermore, oral contraceptive hormonal pills are anticipated to have a major share due to their ease of use and availability.
Data Bridge Market Research analyses a growth rate in the hormonal contraceptive market in the forecast period 2023-2030. The expected CAGR of the hormonal contraceptive market tends to be around 4.60% in the mentioned forecast period. The market was valued at USD 16.6 billion in 2022 and would grow to USD 23.79 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hormonal Contraceptive Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Combined Oral Contraceptives, Oral, Contraceptives, Implanted Contraceptives, Injected Contraceptives, Intrauterine, Transdermal Patch Vaginal Ring), Hormone (Androgens, Estrogens, Progestogens, Antiandrogens, Gonadotropins, Others), Age Group (15-24 Years, 25-34 Years, 35-44 Years, Above 44 Years), Gender (Male and Female), End-User (Hospitals, Homecare, Clinics, Gynecology Centers, Ambulatory Surgical Centers (ASC))
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbvie, Inc (U.S.), Afaxys, Inc. (U.S.), Merck & Co Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel)., Bayer AG (Germany), Pfizer Inc. (U.S.), Agile Therapeutics (U.S.), Cupid Ltd. (India), Helm AG (Germany), Church & Dwight Co., Inc (U.S.), Reckitt Benckiser Group PLC (U.K.), Veru Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Novartis AG (Switzerland), Lupin (India), Glenmark Pharmaceuticals (India)
|
|
Market Opportunities
|
|
Market Definition
Hormonal contraceptives are birth control methods that act on the endocrine system. These methods consist of the use of hormones that are normally produced by women, such as estrogen and progesterone, to prevent ovulation and pregnancy. These contraceptives do not protect against HIV or other sexually transmitted infections.
Global Hormonal Contraceptive Market Dynamics
Drivers
- Increase in Strategic Developments by Market Players
Several major companies collaborate with huge organizations or personalities to make people aware of the contraceptives that help avoid pregnancy. For instance, Allergen Plc partnered with Ashley Tisdale for the awareness campaign "Women Who Know" in 2019. The campaign raises awareness in women about the numerous options available for contraception, including Loestrin Fe, a hormonal pill by Allergen. Thus, increasing strategic developments are leading to the global market growth rate.
- Increasing R&D Activities
The increasing investment in R&D and commercialization of several new products are some of the major strategies the major market players adopted to surge their industry share. For instance, Mayne Pharma received U.S. FDA approval for NEXTSTELLIS and estetrol for avoiding pregnancy in 2021. It is the only contraceptive with E4, a plant-based estrogen with few potential benefits than the other estrogens. Thus, this factor boosts market growth.
Opportunities
- Increasing Demand for Oral Contraceptives
Oral contraceptive hormonal pills are anticipated to have a major share due to ease of use and availability. In addition, several companies are focusing on new product launches and advancing the combination of hormonal contraceptives, likely to boost the market growth. For instance, Perrigo Company Plc submitted its application to the United States Food and Drug Administration (U.S. FDA) for one of the first over-the-counter (OTC) birth control pills in the United States in 2022. The company has applied for an Rx-to-OTC switch for Opill, a progestin daily birth control pill. The growing innovations in oral contraceptives are expected to surge the market growth.
- Rising Healthcare Expenditure by Organizations
There is an increasing healthcare expenditure by different organizations that lead to armlet growth. For instance, the Government of Canada made a 10-year commitment to reach an average of USD 1.4 billion in funding annually by 2023 to support women's, children's, and adolescents' health worldwide in 2019. It is stated that USD 700 million of this funding is dedicated to sexual and reproductive health and rights (SRHR). The initiative is anticipated to work on the awareness of the use of contraceptives and reproductive health services. Thus, this factor boosts market growth.
Restraints/Challenges
- Lack of Awareness Regarding Contraception
The lack of understanding while using these long-term hormonal contraceptive pills leads to the restricted use of these pills. In underdeveloped countries, the social stigma is related to contraception methods. The high cost of these methods and pills is mainly responsible for the low uptake and acceptability. Thus, this factor restricts the market growth.
- Side-Effects of Hormonal Contraceptive
The severe side effects associated with the treatment process restrict the market growth. In rare cases, the side effects are very extreme such as blood clots in the legs, heart attacks, stroke, liver disorders, and gallbladder disease. These side effects of hormonal contraceptives will restrict sales during the forecast period.
This global hormonal contraceptive market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hormonal contraceptive market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In December 2021, Cooper Surgical, Inc. acquired Generate Life Sciences. This acquisition aids Cooper in enhancing its reproductive segment. Generate Life Sciences, a top provider of donor eggs and sperm for fertility treatments, fertility cryopreservation services, and newborn stem cell storage, for a purchase price of around $1.6 billion.
Global Hormonal Contraceptive Market Scope
The global hormonal contraceptive market is segmented on the basis of product, hormone, age group, gender, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Combined Oral Contraceptives
- Oral
- Contraceptives
- Implanted Contraceptives
- Injected Contraceptives
- Intrauterine
- Transdermal Patch Vaginal Ring
Hormone
- Androgens
- Estrogens
- Progestogens
- Antiandrogens
- Gonadotropins
- Others
Age Group
- 15-24 Years
- 25-34 Years
- 35-44 Years
- Above 44 Years
Gender
- Male
- Female
End User
- Hospitals
- Homecare
- Clinics
- Gynecology Centers
- Ambulatory Surgical Centers (ASC)
Hormonal Contraceptive Market Regional Analysis/Insights
The hormonal contraceptive market is analyzed and market size insights and trends are provided by product, hormone, age group, gender, and end user as referenced above.
The major countries covered in the hormonal contraceptive market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominated the market growth for the hormonal contraceptive market throughout the forecasted period because of the increase in the per capita income and the strong incidence of major market players. Additionally, the rise in the consciousness associated with sexual health and the increasing number of accidental pregnancies led to market growth.
Asia-Pacific expects a high market growth due to growing healthcare expenditure focusing on women's health as a priority. Furthermore, the surge in investment by major market players and strong economic growth is further expected to boost the growth of the hormonal contraceptive market in the region in the upcoming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hormonal Contraceptive Market Share Analysis
The global hormonal contraceptive market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hormonal contraceptive market
Key players operating in the hormonal contraceptive market include:
- Abbvie, Inc (U.S.)
- Afaxys, Inc. (U.S.)
- Merck & Co Inc. (U.S.)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- Bayer AG (Germany)
- Pfizer Inc. (U.S.)
- Agile Therapeutics (U.S.)
- Cupid Ltd. (India)
- Helm AG (Germany)
- Church & Dwight Co., Inc (U.S.)
- Organon group of companies (U.S.)
- Reckitt Benckiser Group PLC (U.K.)
- Veru Inc. (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Novartis AG (Switzerland)
- Lupin (India)
- Glenmark Pharmaceuticals (India)
SKU-